{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:58Z","timestamp":1793041978034,"version":"4.5.0"},"reference-count":23,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed\/refractory multiple myeloma (RRMM) patients who have received one to three prior line(s) of therapy (LOT[s]) including an immunomodulatory agent and a proteasome inhibitor, and are refractory to lenalidomide. These analyses estimate the relative efficacy between cilta-cel and other common treatment regimens, for which no direct comparative evidence is available.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Patient data were available from the CARTITUDE-4, CASTOR, CANDOR and APOLLO RCTs. Imbalances between cohorts on key patient characteristics were adjusted for using inverse probability of treatment weighting (IPTW). Relative efficacies were estimated with response rate ratios (RRs) and 95% confidence intervals (CIs) for overall response rate (ORR), very good partial response or better rate (\u2265VGPR) and complete response or better rate (\u2265CR), and with hazard ratios (HRs) and 95% CIs for progression-free survival (PFS). Sensitivity analyses using different analytical methods and additional covariates were explored.\n            <jats:bold>Results:<\/jats:bold>\n            Key characteristics were well balanced across cohorts after IPTW. Cilta-cel showed statistically significant benefit in PFS (HRs: 0.11\u20130.51), \u2265VGPR (RRs: 1.51\u20135.13) and \u2265CR (RRs: 2.90\u201335.24) versus all comparators, and statistically significant improvements in ORR over most comparator regimens (RRs: 1.22\u20131.90). Results were consistent across sensitivity analyses.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Cilta-cel demonstrated benefit over other common treatment regimens, highlighting its potential to become a new standard of care option for lenalidomide-refractory RRMM patients with one to three prior LOT(s). These comparisons help to demonstrate the improved efficacy of cilta-cel in countries where the standard of care may differ from DPd\/PVd.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0080","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:11:01Z","timestamp":1724145061000},"source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-2437","authenticated-orcid":false,"given":"Winfried","family":"Alsdorf","sequence":"first","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-9120","authenticated-orcid":false,"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica\u00a0NV, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[{"name":"Janssen-Cilag SpA, 20126,\u00a0Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[{"name":"Jan-Cilag Farmac\u00eautica, 2740-262, Porto Salvo, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hernando","sequence":"additional","affiliation":[{"name":"Janssen-Cilag S.A., 28703, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cost","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M","family":"Schecter","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ 08873, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-9644","authenticated-orcid":false,"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[{"name":"Hosp. Clinic I Provincial de Barcelona, 08036, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8821-9397","authenticated-orcid":false,"given":"Margherita","family":"Ursi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria, Policlinico Sant'orsola Malpighi di Bologna, 40138, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_10_2_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/phar.1871","article-title":"Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy","volume":"37","author":"Chung C","year":"2017","unstructured":"Chung C. Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy. Pharmacotherapy 37(1), 129\u2013143 (2017).","journal-title":"Pharmacotherapy"},{"issue":"3","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ccr.2013.08.014","article-title":"Why proteasome inhibitors cannot ERADicate multiple myeloma","volume":"24","author":"Orlowski RZ","year":"2013","unstructured":"Orlowski RZ. Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell 24(3), 275\u2013277 (2013).","journal-title":"Cancer Cell"},{"issue":"2","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson KC","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 22(2), 231\u2013239 (2008).","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang Y","year":"2020","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J. Hematol. Oncol. 13(1), 150 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"643490","DOI":"10.3389\/fonc.2021.643490","article-title":"Treatment of lenalidomide exposed or refractory multiple myeloma: network meta-analysis of lenalidomide-sparing regimens","volume":"11","author":"Botta C","year":"2021","unstructured":"Botta C, Martino EA, Conticello C Treatment of lenalidomide exposed or refractory multiple myeloma: network meta-analysis of lenalidomide-sparing regimens. Front. Oncol. 11, 643490 (2021).","journal-title":"Front. Oncol."},{"key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"703233","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat CSY","year":"2021","unstructured":"Lecat CSY, Taube JB, Wilson W Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma. Front. Oncol. 11, 703233 (2021).","journal-title":"Front. Oncol."},{"issue":"4","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389(4), 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo A","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(8), 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase III study","volume":"23","author":"Usmani SZ","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos M-V Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase III study. Lancet Oncol. 23(1), 65\u201376 (2022).","journal-title":"Lancet Oncol."},{"issue":"6","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase III trial","volume":"22","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase III trial. Lancet Oncol. 22(6), 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"issue":"3","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01840832","article-title":"Prognostic factors in clinical trials","volume":"22","author":"Dahlberg S","year":"1992","unstructured":"Dahlberg S, Liu PY. Prognostic factors in clinical trials. Breast Cancer Res. Treat. 22(3), 193\u2013196 (1992).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jha2.312","article-title":"Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma","volume":"3","author":"Martin T","year":"2022","unstructured":"Martin T, Krishnan A, Yong K Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem. 3(1), 97\u2013108 (2022).","journal-title":"EJHaem."},{"issue":"1","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS Clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel K","year":"2022","unstructured":"Weisel K, Martin T, Krishnan A Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS Clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. Clin. Drug Investig. 42(1), 29\u201341 (2022).","journal-title":"Clin. Drug Investig."},{"issue":"24","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld P","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24), 2955\u20132962 (2016).","journal-title":"Blood"},{"issue":"521","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li F","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J. Am. Stat. Assoc. 113(521), 390\u2013400 (2018).","journal-title":"J. Am. Stat. Assoc."},{"issue":"7","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou G","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am. J. Epidemiol. 159(7), 702\u2013706 (2004).","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye NC","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G An introduction to inverse probability of treatment weighting in observational research. Clin. Kidney J. 15(1), 14\u201320 (2022).","journal-title":"Clin. Kidney J."},{"issue":"8","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n MA","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183(8), 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch PM","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81(3), 515\u2013526 (1994).","journal-title":"Biometrika"},{"key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston P","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med. Res. Methodol. 13, 152 (2013).","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00273171.2022.2046997","article-title":"Identifying and estimating causal moderation for treated and targeted subgroups","volume":"58","author":"Dong N","year":"2023","unstructured":"Dong N, Kelcey B, Spybrook J. Identifying and estimating causal moderation for treated and targeted subgroups. Multivariate Behav. Res. 58(2), 221\u2013240 (2023).","journal-title":"Multivariate Behav. Res."},{"issue":"6","key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/10543406.2020.1815035","article-title":"Statistical and practical considerations in designing of immuno-oncology trials","volume":"30","author":"Mukhopadhyay P","year":"2020","unstructured":"Mukhopadhyay P, Huang W, Metcalfe P, Ohrn F, Jenner M, Stone A. Statistical and practical considerations in designing of immuno-oncology trials. J. Biopharm. Stat. 30(6), 1130\u20131146 (2020).","journal-title":"J. Biopharm. Stat."},{"issue":"8","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3324\/haematol.2022.280482","article-title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice","volume":"108","author":"Mateos MV","year":"2023","unstructured":"Mateos MV, Weisel K, Martin T Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica 108(8), 2192\u20132204 (2023).","journal-title":"Haematologica"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:25:34Z","timestamp":1724671534000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.57264\/cer-2024-0080"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0080","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"article-number":"e240080"}}